Vecima Acquires Falcon V Systems, Provider of Innovative Software Orchestration Platform for Cable, Fiber, and Mobile Access Networks
11.10.2024 13:30:00 CEST | Business Wire | Press release
Combination of Vecima’s Entra Cloud™ and Falcon’s Principal Core and Test Suite will help operators accelerate and simplify cable, fiber, and mobile access network and service flow convergence, using automated software tools and testing Charter Communications will be the initial customer, signing a multi-year deal to deploy both the Principal Core and Test Suite Falcon V Systems’ open, interoperable platform supports multiple vendors’ vCMTS platforms, including Vecima’s Entra® vCMTS & Entra® vPON Manager
Vecima Networks, Inc. (TSX: VCM) today announced that, through its subsidiary Vecima Technology B.V., it has acquired Falcon V Systems, a Poland-based provider of vendor-agnostic, virtualized software solutions and services for Broadband Service Providers worldwide.
Vecima has acquired all outstanding Falcon V Systems shares, as well as the company’s technology, intellectual property, and talent. With the close of the acquisition today, Vecima will onboard a significant portion of the Falcon V team which will be integrated into Vecima’s Video & Broadband Solutions business, comprising its market-leading Entra broadband access portfolios and talent.
Falcon V Systems’ key products will be integrated into Vecima’s Entra Cloud™ portfolio of open, interoperable, cloud-native applications that help cable operators transform their networks for next-generation broadband access:
-
Falcon V Systems’ Principal Core manages across multiple cable, fiber, and mobile cores, allowing a multivendor environment, with seamless integration across the OSS/BSS ecosystem — a convergence of services not possible previously.
- The Test Suite is a comprehensive set of tools, focused on helping Broadband Service Providers accelerate deployments and feature enhancements, through an automated, end-to-end test environment.
“I’m incredibly proud of what the Falcon V team has accomplished, and I extend my sincerest thanks to our talented Falcon team, our partners, and our customers,” said Ulf Andersson, CEO of Falcon V Systems. “Vecima will take our work forward and bring it to market on a global scale, unlocking the potential of the Falcon V technology and team.”
“Our work over the last several years with Falcon V Systems has been a critical component in our long-term access architecture strategy, enabling us to simplify and enhance the subscriber experience,” said Justin Colwell, Executive Vice President, Connectivity Technology, Charter Communications. “We plan to deploy the Principal Core, which will be a component of Vecima’s vCMTS solution, along with the Test Suite, and look forward to working closely with Vecima to lead wider adoption of the Entra Cloud platform across the industry.”
“Flexibility and interoperability are the cornerstone of Vecima’s unique approach to access networks and the hallmark of Falcon V Systems’ automation and orchestration software,” said Clay McCreery, Chief Operating Officer at Vecima. “With this acquisition, Vecima expands its research and development footprint into Europe with an expert team of DAA technologists in Poland. Falcon V Systems will be able to take advantage of Vecima’s global scale, existing vCMTS and PON platforms, and extensive customer relationships.”
“Vecima’s mission is to empower service providers globally with the transformative solutions that usher in the new multi-gigabit connectivity era to come,” said Sumit Kumar, Vecima President and Chief Executive Officer. “We are embarking on a new phase of growth, and by adding the Falcon V Systems team and technology to our expansive industry-leading broadband access portfolio, we broaden, once more, our ability to meet the evolving network convergence needs of Broadband Service Provider customers worldwide. With the Falcon team & Charter’s long-term partnership, this acquisition further deepens Vecima’s leadership in the Broadband Service Provider segment.”
About Falcon V Systems
Falcon V Systems is an independent challenger that delivers a cost-effective, scalable, and non-proprietary open DAA solution for Broadband Service Providers based on Software Defined Networking (SDN) and Network Functions Virtualization (NFV). This non-monolithic, agile architecture will enable more efficient use of network assets, data centers, and cloud assets. Thanks to open interfaces, the solution evolves along with the growth of needs and supports the cooperation between operators and other vendors.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at vecima.com.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words “believes”, “may”, “plans”, “will”, “anticipates”, “intends”, “could”, “estimates”, “expects”, “forecasts”, “projects” and similar expressions, and the negative of such expressions.
Forward-looking information in this news release includes, but is not limited to, any statements respecting: Vecima will onboard a significant portion of the Falcon V team which will be integrated into Vecima’s Video & Broadband Solutions business; closing of the transaction will allow Vecima to expand its research and development footprint into Europe; Falcon V Systems’ key products will be integrated into Vecima’s Entra Cloud™ portfolio; Charter Communications’ plans to deploy the Principal Core and Test Suite.
The forward-looking statements are based on the current expectations of the management of Vecima and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated.
A more complete discussion of the risks and uncertainties facing Vecima is generally disclosed under the heading “Risk Factors” in the Company’s Annual Information Form dated September 19, 2024, as well as the Company’s continuous disclosure filings with Canadian securities regulatory authorities available at www.sedarplus.ca. All forward-looking information herein is qualified in its entirety by this cautionary statement, and Vecima disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events, or developments, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010671688/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom